From CNBC: 2025-01-22 13:24:48

Abbott Laboratories reported mixed fourth-quarter results and 2025 guidance with revenue of $10.97 billion, missing estimates of $11.01 billion. Organic sales were up 10.1%, and adjusted EPS of $1.34 met expectations. The medical device maker’s stock rose over 1% as investors see potential for a strong 2025. CEO Robert Ford highlighted strong momentum and growth prospects for the year ahead. The company’s medical devices segment, particularly diabetes care, showed robust growth. Sales in nutrition and diagnostics also contributed to overall revenue growth. Abbott projects full-year organic sales growth of 7.5% to 8.5% and an adjusted gross profit margin expansion of 80 basis points. The company expects an adjusted operating margin of 23.5% to 24% in 2025. Management’s conservative guidance positions Abbott Labs for a positive year ahead.



Read more at CNBC:: Abbott shares climb despite a mixed quarter. What we want to see before we buy more